Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TNKS | O95271 | 3/20 | 0.57 |
| ▸ | HTR3A | P46098 | 4/20 | 0.51 |
| ▸ | HRH4 | Q9H3N8 | 4/20 | 0.51 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.43 |
| ▸ | POLB | P06746 | 2/20 | 0.43 |
| ▸ | MAPK1 | P28482 | 2/20 | 0.43 |
| ▸ | APP | P05067 | 2/20 | 0.42 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.42 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.42 |
| ▸ | MEN1 | O00255 | 1/20 | 0.42 |
| ▸ | CNR1 | P21554 | 1/20 | 0.42 |
| ▸ | CNR2 | P34972 | 1/20 | 0.42 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.42 |
| ▸ | MAPT | P10636 | 1/20 | 0.41 |
| ▸ | TSHR | P16473 | 1/20 | 0.41 |
| ▸ | FYN | P06241 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL25138085 | 0.84 | TNKS (0.46) | TNKSHTR3AHRH4ALDH1A1POLB | |
| SCHEMBL3406553 | 0.84 | PRKDC (0.52) | ALDH1A1MAPK1KMT2AKDM4EMEN1 | |
| SCHEMBL15515174 | 0.84 | PRKDC (0.52) | ALDH1A1MAPK1KMT2AKDM4EMEN1 | |
| SCHEMBL2383211 | 0.81 | HRH4 (0.52) | TNKSHTR3AHRH4ALDH1A1POLB | |
| SCHEMBL9147047 | 0.75 | HTR3A (0.56) | TNKSHTR3AHRH4MAPK1KMT2A | |
| SCHEMBL5230511 | 0.75 | CNR2 (0.47) | TNKSHTR3AAPPKDM4ECNR1 | |
| SCHEMBL16625344 | 0.73 | TNKS (1.00) | TNKSHTR3AHRH4ALDH1A1KDM4E | |
| SCHEMBL2895959 | 0.73 | CHRM2 (0.41) | HTR3AAPPFYN | |
| SCHEMBL25138087 | 0.71 | TNKS (0.48) | TNKSHTR3AHRH4ALDH1A1POLB | |
| SCHEMBL14463302 | 0.71 | APP (0.56) | APPFYN |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7772256-B2 | 2-heteroaryl substituted benzothiophenes and benzofuranes 709 | ASTRAZENECA AB (SE) | 2010-08-10 | — | — | US | disclosed |
| US-7772256-B2 | 2-heteroaryl substituted benzothiophenes and benzofuranes 709 | ASTRAZENECA AB (SE) | 2010-08-10 | — | — | US | disclosed |
| US-20080221149-A1 | 2-[6-(methylamino)pyridin-3-yl]-1-benzofuran-5-ol; for imaging amyloid deposits in living patients | ASTRAZENECA AB (SE) | 2008-09-11 | — | — | US | disclosed |
| US-20080221149-A1 | 2-[6-(methylamino)pyridin-3-yl]-1-benzofuran-5-ol; for imaging amyloid deposits in living patients | ASTRAZENECA AB (SE) | 2008-09-11 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080221149-A1 | 2-[6-(methylamino)pyridin-3-yl]-1-benzofuran-5-ol; for imaging amyloid deposits in living patients | PSEN1, APP, PSEN2 | TNKS 4652/4885HTR3A 1067/4885HRH4 3114/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.